Eli Lilly reaches $2.75 billion deal with Insilico to bring AI-developed drugs to the global market
This article details a significant $2.75 billion deal where Eli Lilly will partner with Insilico to bring AI-discovered drugs to market. For financial advisors, this highlights the increasing commercialization and market value of AI in the pharmaceutical sector, signaling a growing trend of AI adoption impacting investment opportunities and industry analysis.